• Welcome, Guest. Please login or register.
    August 23, 2019, 07:59:51 PM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:

thalpal.com

Click to visit us on Facebook


If you have any problems registering or signing in, please send an email to: andy@thalpal.com
Please do not send questions about thalassemia to this address.


Administrators
Andy
Danielle

Thalassemia Patients and Friends and thalpal © A. Battaglia 2019





55096 Posts in 5864 Topics by 6146 Members
Latest Member: cdarr

Forum Tip: 
You can change your member name in your profile, under "Account Related Settings," so you don't have to re-register to change it.
« previous next »
Pages: « 1 2 3 4 5 6 7 8 9 10 11 12 13 » Go Down Print
Author Topic: Bluebird Bio Releases Data on Current Gene Therapy Trials  (Read 95043 times)
Canadian_Family
Supreme Member
*****
Offline Offline

Posts: 1064



« Reply #150 on: October 13, 2016, 09:55:06 AM »

October 13, 2016 highlights. Read for full details....

http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=2211455

Important update:

LentiGlobin Manufacturing Data: A Head-to-Head In Vitro Comparison of Process 1 and Process 2
bluebird bio has recently modified the process by which the patient’s cells are transduced in LentiGlobin clinical studies with the addition of enhancers during the manufacturing process. The goal of manufacturing Process 2 is to increase the percentage of cells successfully transduced, thereby increasing vector copy number (VCN) in the drug product that is given to the patient.

Using retained samples of CD34+ stem cells collected from patients in the HGB-204 (Northstar) and HGB-206 studies, the company was able to demonstrate in a head-to-head in vitro comparison that manufacturing Process 2 substantially increased the percentage of cells transduced and VCN, as compared to manufacturing Process 1.

This in vitro data from Process 2 showed an average increase of approximately three-fold in vector-positive cells and VCN across all patient samples tested. Process 2 has been successfully scaled up for clinical manufacturing, and all LentiGlobin clinical trials moving forward will use manufacturing Process 2, including the Phase 3 HGB-207 (Northstar-2) trial and the Phase 1 HGB-206 clinical trial.

bluebird bio also highlighted progress it has made in moving from adherent manufacturing of lentiviral vectors to potentially more efficient suspension manufacturing, consistently achieving the targeted potency, purity and VCNs at increased scale.
Logged

Regards.
catchR
Active Member
**
Offline Offline

Posts: 88


« Reply #151 on: October 14, 2016, 08:50:46 AM »

That's some good news, hopefully bluebird gets there quickly.

regards,
R
Logged
Parin
Junior Member
***
Offline Offline

Location: USA

Gender: Male
Posts: 136


« Reply #152 on: October 14, 2016, 07:22:10 PM »

Wow, things are moving with some pace
Logged
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8583


Will thal rule you or will you rule thal?


« Reply #153 on: October 15, 2016, 12:24:16 PM »

I emailed the new rep. Hopefully, I will get a reply.
Logged

Andy

All we are saying is give thals a chance.
Sharmin
Global Moderator
Supreme Member
*****
Offline Offline

Location: Canada

Gender: Female
Posts: 4155


Little A


« Reply #154 on: October 18, 2016, 11:37:34 AM »

Canadian_Family,

Thank you kindly for sharing this is great news for all thal patients - especially beta zeros!

Logged

Sharmin
Canadian_Family
Supreme Member
*****
Offline Offline

Posts: 1064



« Reply #155 on: October 19, 2016, 11:10:14 AM »

My personal take on the news is that there is not much to report in December during ASH conference. The enhancers will take time and new data will not be available until 2017 and beyond. The catalyst that Blue will show positive data from process 1 is wasted. Looking forward to 2017 and beyond.
Logged

Regards.
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8583


Will thal rule you or will you rule thal?


« Reply #156 on: October 19, 2016, 05:07:25 PM »

Bluebird will be presenting on 204, 205 and 206 at ASH
Logged

Andy

All we are saying is give thals a chance.
Parin
Junior Member
***
Offline Offline

Location: USA

Gender: Male
Posts: 136


« Reply #157 on: October 20, 2016, 10:48:47 AM »

Thanks Andy.

Is it 204, 205 and 206 are beta Zero?
Logged
Canadian_Family
Supreme Member
*****
Offline Offline

Posts: 1064



« Reply #158 on: October 20, 2016, 12:35:33 PM »

Thanks for the update Andy. Helpful.
Logged

Regards.
Canadian_Family
Supreme Member
*****
Offline Offline

Posts: 1064



« Reply #159 on: November 03, 2016, 09:29:32 AM »

Update Nov 3, 2016

In Northstar, the largest study of gene therapy in patients with TDT to date, all patients have demonstrated robust expression of therapeutic hemoglobin, or HbAT87Q, with a safety profile that is consistent with autologous transplantation. We are particularly pleased to see that, across the Northstar and HGB-205 studies, all patients with non-β0/β0 genotypes and at least 12 months of follow-up remained free of transfusions for up to 31 months, adding to the growing body of evidence supporting the potential for LentiGlobin to become a transformative therapy for these patients. Additionally, we have seen clinically meaningful reductions in transfusions for patients with β0/β0 genotypes. We believe that the implementation of manufacturing process 2 going forward has the potential to further reduce transfusion requirements for patients with β0/β0 genotypes, and we will evaluate that hypothesis in our planned Phase 3 HGB-212 trial.

Details http://www.streetinsider.com/

Abstract Results, as of June 27, 2016 Data Cut-off:

Eighteen patients have received LentiGlobin drug product: eight with β0/β0 genotypes and 10 with non-β0/β0 genotypes
The median vector copy number (VCN) in drug product (DP) was 0.7 (range: 0.3 – 1.5 copies/diploid genome) and the median cell dose was 8.1 x 106 CD34+ cells/kg (range: 5.2 – 18.1 x 106 cells/kg)
The median in vivo VCN in patients with at least six months of follow-up was 0.4 copies/diploid genome (range: 0.2-1.0; n=13)
Patients of all genotypes with at least six months of follow-up (n=14) achieved a median HbAT87Q level of 4.7 g/dl and robust HbAT87Q production was sustained in the 10 patients with ≥12 months of follow-up
All patients with non-β0/β0 genotypes and at least 12 months follow-up (n=5) have discontinued transfusions and remain free of transfusions (median 19.4 months without transfusion; range: 15.3 to 24.0 months)
All patients with β0/β0 genotypes have considerably reduced transfusion requirements (median 60% reduction; from median 171.9 ml/kg/year at baseline [range: 168.1- 223.2 ml/kg/year] to 67.8 ml/kg/year post-treatment [range: 14.8 to 123.7 ml/kg/year])
The safety profile remains consistent with autologous stem cell transplantation with no ≥ Grade 3 drug product-related adverse events (AEs) reported.
Logged

Regards.
Andy Battaglia
Administrator
Supreme Member
*****
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8583


Will thal rule you or will you rule thal?


« Reply #160 on: November 03, 2016, 02:41:26 PM »

Bluebird's link on this announcement. http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=2219192

Logged

Andy

All we are saying is give thals a chance.
Parin
Junior Member
***
Offline Offline

Location: USA

Gender: Male
Posts: 136


« Reply #161 on: December 14, 2016, 11:09:55 AM »

bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product in Northstar-2 (HGB-207) Phase 3 Trial of Patients with Transfusion-Dependent β-Thalassemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 14, 2016-- bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced treatment of the first patient in Northstar-2, the Phase 3 study of its LentiGlobin drug product in patients with transfusion-dependent β-thalassemia (TDT) and non-β0/β0 genotypes. This study will use LentiGlobin drug product manufactured with the addition of transduction enhancers intended to increase the drug product vector copy number and percent of cells transduced. The study’s primary endpoint is the proportion of treated subjects who meet the definition of "transfusion independence," defined as total hemoglobin levels of at least 9g/dL without any RBC transfusions for a continuous period of at least 12 months at any time during the study.

“The opening of our first Phase 3 trial in TDT is an exciting milestone for bluebird,” said David Davidson, chief medical officer. “At ASH we presented interim LentiGlobin data from the Northstar study showing substantial and durable treatment effects, with all patients with non-β0/β0 genotypes and at least twelve months of follow-up achieving freedom from transfusions. We are hopeful that our new manufacturing process incorporating transduction enhancers will build upon these results and may provide even better outcomes for patients. It is an encouraging start for Northstar-2 to have achieved a robust drug product VCN of 2.9 c/dg and 77% LVV+ for our first treated patient. We are tremendously grateful to the patients, families, study investigators, and site staff who have participated in our LentiGlobin program and enabled progress toward our goal of improving the lives of patients with TDT.”

“The current results of the HGB-204 and HGB-205 LentiGlobin studies show a reduction, and in some cases, elimination of RBC transfusions in patients with TDT,” said Mark C. Walters, M.D., UCSF Benioff Children’s Hospital Oakland, a principal investigator on the study. “The current study, Northstar-2, will test a new manufacturing method to increase the VCN in the drug product. If it is successful, this new enhanced transduction method could expand the number of patients who no longer need transfusions after the gene therapy treatment.”

bluebird bio is also moving forward with plans to initiate Northstar-3 (HGB-212), a Phase 3 trial of LentiGlobin drug product in patients with transfusion-dependent β-thalassemia with the β0/β0 genotype. This study will also be conducted under the new manufacturing process, and is expected to begin enrolling patients in 2017. The primary endpoint of this planned study is transfusion reduction.


http://investor.bluebirdbio.com/phoenix.zhtml?c=251820&p=irol-newsArticle&ID=2229663
Logged
Canadian_Family
Supreme Member
*****
Offline Offline

Posts: 1064



« Reply #162 on: February 03, 2017, 09:28:24 AM »

First SCD patient treated under the amended study protocol in HGB-206.  For details pl. follow the link.

http://finance.yahoo.com/news/bluebird-bio-announces-first-patient-130000772.html
Logged

Regards.
Parin
Junior Member
***
Offline Offline

Location: USA

Gender: Male
Posts: 136


« Reply #163 on: February 04, 2017, 06:57:09 PM »

Thanks for sharing..its good news.
Logged
Hafiz Akhtar
Active Member
**
Offline Offline

Posts: 28


« Reply #164 on: February 08, 2017, 11:35:11 PM »

canadian Family. pl inform when will Thal cure. if not fully cured the transfusion burden may b reduced. v r tired now. believe me
Logged
Pages: « 1 2 3 4 5 6 7 8 9 10 11 12 13 » Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!